Immunotherapies such as monoclonal antibodies, bispecific antibodies (Bi-specific T-cell engagers or BiTEs) and adoptive T-cell therapies (e.g. CAR-modified T-cell) have provided great advances in cancer treatment. However, testing new therapies is not without risk. The most common and potentially severe
